AllergyTalk Episode 45 (Non-CME) – Should We Wait To Skin Test After A Food Allergy Reaction?

Price: FREE for members and non-members
CME is not offered for this episode

Speakers: Gerald Lee, MD, Stanley Fineman, MD and Shyam Joshi, MD

AllergyTalk is a podcast designed to provide easy access to research summaries from Allergy Watch and recommendations from subject matter experts in order to bring physicians up to date onthe latest advances in the field of allergy and immunology.

The following AllergyWatch articles are covered in this episode:

1.  Gut microbiota maturity mediates the protective effect of siblings on food allergy.
2.  Duration of skin prick test refractory period following food-induced allergic reactions.
3.  Clinical and immunological phenotypes of selective IgM deficiency in children: Results from a multicenter study.

Target Audience

Primary Care Providers
Fellows-in-Training

Learning Objectives

Upon completion of this podcast, the participant should be able to:
1. Discuss the effect of number of siblings and gut microbiota on food allergy risk.
2. Name the duration of the refractory period of skin tests after a food allergy reaction.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Course opens: 
08/22/2024
Course expires: 
12/31/2025
Rating: 
0

All relevant financial relationships with ineligible companies have been mitigated.

Gerald Lee, MD
Speaker: Novartis

Stanley Fineman, MD
Speaker: Takeda; Researcher: DBV, Novartis, Alladapt

Shyam Joshi, MD
Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda
Consultant, Executive Role: Nectar Allergy

Please login or create an account to take this course.